Commentaries
A Sea Change in the Treatment of Chronic Urticaria
Quién lo ha visto y quién lo ve? Tratando la urticaria crónica
A.M. Giménez-Arnau
Servicio de Dermatología, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain
Leído
3415
Vecesse ha leído el artículo
1424
Total PDF
1991
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S1578219019301064" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.11.021" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "2115" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:260" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3 "HTML" => 3 ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S0001731018305337" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.11.003" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "2115" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:260" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 327 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 210 "PDF" => 116 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>" "titulo" => "Quién lo ha visto y quién lo ve? Tratando la urticaria crónica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "260" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "A Sea Change in the Treatment of Chronic Urticaria" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A.M. Giménez-Arnau" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A.M." "apellidos" => "Giménez-Arnau" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219019301064" "doi" => "10.1016/j.adengl.2018.11.021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019301064?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018305337?idApp=UINPBA000044" "url" => "/00017310/0000011000000004/v2_201905040606/S0001731018305337/v2_201905040606/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S157821901930143X" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.03.018" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "2198" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:261" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "HTML" => 2 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Hidradenitis Suppurativa: Need for Early Diagnosis and Management of the Disease and Associated Conditions" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "261" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hidradenitis Supurativa: Necesidad de Un Diagnóstico e Intervención Precoz Sobre La Enfermedad y Sus Comorbilidades" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "G Roustan" "autores" => array:1 [ 0 => array:2 [ "nombre" => "G" "apellidos" => "Roustan" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101930064X" "doi" => "10.1016/j.ad.2019.01.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101930064X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821901930143X?idApp=UINPBA000044" "url" => "/15782190/0000011000000004/v1_201905070820/S157821901930143X/v1_201905070820/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219019300873" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.12.010" "estado" => "S300" "fechaPublicacion" => "2019-05-01" "aid" => "2129" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2019;110:259" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9 "formatos" => array:2 [ "HTML" => 7 "PDF" => 2 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Hidradenitis Suppurativa as a Systemic Disease: Association With Metabolic Syndrome" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "259" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La hidradenitis supurativa como enfermedad sistémica: asociación a síndrome metabólico" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Martorell" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Martorell" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101830574X" "doi" => "10.1016/j.ad.2018.12.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101830574X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019300873?idApp=UINPBA000044" "url" => "/15782190/0000011000000004/v1_201905070820/S1578219019300873/v1_201905070820/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "A Sea Change in the Treatment of Chronic Urticaria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "260" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "A.M. Giménez-Arnau" "autores" => array:1 [ 0 => array:3 [ "nombre" => "A.M." "apellidos" => "Giménez-Arnau" "email" => array:1 [ 0 => "anamariagimenezarnau@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Quién lo ha visto y quién lo ve? Tratando la urticaria crónica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic urticaria is primarily an autoimmune disease, mediated either by immunoglobulin (Ig) E or IgG, acting on the high-affinity IgE receptor (FcɛIgERI), which is overexpressed both in skin mastocytes and circulating basophils. Different exacerbating factors contribute to the manifestation of the condition as well as its conversion to a chronic process. Regardless of whether the spontaneous or inducible type of disease is present, the chosen therapy should be effective and safe, and it needs to be maintained for long periods of between 1 to 5 years. The therapeutic goal is to keep the patient completely free of symptoms so that she or he can lead a normal life. With this aim, omalizumab has become an essential addition to the therapeutic armamentarium for the treatment of chronic urticaria. The authors of the commented article reflect on their experience with the use of this monoclonal antibody in daily clinical practice in accordance with the recommendations of the most recent treatment guidelines.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a> In daily clinical practice, their patients achieve better therapeutic outcomes than in clinical trials, measured in terms of the urticaria activity score (UAS) in the 7 days before the study visit. Only 1 phase II study, EXCUISITE, reports percentages of complete control similar to those observed in clinical practice. That study only included patients with IgE anti-peroxidase; that is, patients were selected for an FcɛIgERI activation mechanism or autoallergy. This suggest that this type I autoimmunity mechanism is the predominant one. In contrast, IgG anti-FcɛIgERI, implicated in type 2<span class="elsevierStyleHsp" style=""></span>b autoimmunity mechanism, is less frequent. The authors of the commented article analyzed clinical response and complete response at 3 and 6 months of treatment and found higher percentages of responders than those reported in the clinical trials. To define predictors of response, they link later complete response with those patients with longer-standing urticaria (≥<span class="elsevierStyleHsp" style=""></span>18 months), who are perhaps the most refractory patients. The article does not discuss studies that suggested that this group of patients might be affected by type IIb autoimmunity as indicated by a positive autologous serous skin test (ASST) or positivity for functional serum autoantibodies. The authors report agreement with previous studies such as the study by Curto-Barredo et al.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a> that the slowest response to omalizumab can also be linked to the use immediately beforehand of immunosuppressive medication, such as ciclosporin A. This was the observation of the authors of the Xarxa d’Urticària Catalana i Balear (XUrCB) in a cohort of 286 patients in a bivariate analysis. To finish, we would like to congratulate the authors on the efforts to systematize their experience in the management of chronic urticaria using omalizumab. This is the only way to properly evaluate our day-to-day work.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Giménez-Arnau A. Quién lo ha visto y quién lo ve? Tratando la urticaria crónica. Actas Dermosifiliogr. 2019;110:260.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib0015" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La efectividad del tratamiento con omalizumab en la vida real es menor en pacientes con urticaria crónica de más de 18 meses de evolución y tratamiento inmunosupresor previo" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "X. Cubiró" 1 => "J. Spertino" 2 => "E. Rozas-Muñoz" 3 => "E. Serra-Baldrich" 4 => "L. Puig" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2018.09.009" "Revista" => array:2 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2018" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0020" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Curto-Barredo" 1 => "J. Spertino" 2 => "I. Figueras-Nart" 3 => "V. Expósito-Serrano" 4 => "A. Guilabert" 5 => "G. Melé-Ninot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.16379" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2018" "volumen" => "179" "paginaInicial" => "210" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29368377" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011000000004/v1_201905070820/S1578219019301064/v1_201905070820/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011000000004/v1_201905070820/S1578219019301064/v1_201905070820/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019301064?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 7 | 6 | 13 |
| 2024 Octubre | 56 | 44 | 100 |
| 2024 Septiembre | 62 | 23 | 85 |
| 2024 Agosto | 88 | 60 | 148 |
| 2024 Julio | 59 | 33 | 92 |
| 2024 Junio | 72 | 32 | 104 |
| 2024 Mayo | 60 | 36 | 96 |
| 2024 Abril | 61 | 18 | 79 |
| 2024 Marzo | 57 | 30 | 87 |
| 2024 Febrero | 51 | 30 | 81 |
| 2024 Enero | 51 | 37 | 88 |
| 2023 Diciembre | 46 | 19 | 65 |
| 2023 Noviembre | 74 | 26 | 100 |
| 2023 Octubre | 51 | 21 | 72 |
| 2023 Septiembre | 30 | 28 | 58 |
| 2023 Agosto | 24 | 16 | 40 |
| 2023 Julio | 26 | 32 | 58 |
| 2023 Junio | 39 | 20 | 59 |
| 2023 Mayo | 28 | 19 | 47 |
| 2023 Abril | 22 | 17 | 39 |
| 2023 Marzo | 20 | 22 | 42 |
| 2023 Febrero | 30 | 26 | 56 |
| 2023 Enero | 28 | 27 | 55 |
| 2022 Diciembre | 25 | 34 | 59 |
| 2022 Noviembre | 21 | 19 | 40 |
| 2022 Octubre | 26 | 17 | 43 |
| 2022 Septiembre | 21 | 37 | 58 |
| 2022 Agosto | 23 | 39 | 62 |
| 2022 Julio | 19 | 41 | 60 |
| 2022 Junio | 24 | 28 | 52 |
| 2022 Mayo | 29 | 31 | 60 |
| 2022 Abril | 32 | 25 | 57 |
| 2022 Marzo | 35 | 39 | 74 |
| 2022 Febrero | 23 | 20 | 43 |
| 2022 Enero | 27 | 35 | 62 |
| 2021 Diciembre | 31 | 36 | 67 |
| 2021 Noviembre | 25 | 39 | 64 |
| 2021 Octubre | 36 | 51 | 87 |
| 2021 Septiembre | 18 | 30 | 48 |
| 2021 Agosto | 23 | 25 | 48 |
| 2021 Julio | 15 | 18 | 33 |
| 2021 Junio | 16 | 18 | 34 |
| 2021 Mayo | 33 | 35 | 68 |
| 2021 Abril | 65 | 22 | 87 |
| 2021 Marzo | 76 | 20 | 96 |
| 2021 Febrero | 68 | 23 | 91 |
| 2021 Enero | 42 | 16 | 58 |
| 2020 Diciembre | 39 | 10 | 49 |
| 2020 Noviembre | 10 | 15 | 25 |
| 2020 Octubre | 13 | 6 | 19 |
| 2020 Septiembre | 19 | 8 | 27 |
| 2020 Agosto | 21 | 11 | 32 |
| 2020 Julio | 27 | 9 | 36 |
| 2020 Junio | 21 | 20 | 41 |
| 2020 Mayo | 10 | 7 | 17 |
| 2020 Abril | 19 | 7 | 26 |
| 2020 Marzo | 11 | 11 | 22 |
| 2020 Febrero | 3 | 0 | 3 |
| 2019 Mayo | 3 | 0 | 3 |
Mostrar todo
